A new @ekoermann et al paper in @NatureMedicine compares Gemini with Open evidence with ChatGPT: the winner is.... ... It doesn't matter the paper is already obsolete drvinayprasad.com/p/a-new-pa… via @VPrasadMDMPH

👏 Simple but important, from @ygaritaonaindia and @CCITdk team: across 15,199 patients and 41 phase 3 trials, acquired resistance to immunotherapy correlates to the strength of the response, not the tumor type --> how deep the response goes may matter more than the cancer type

Great research from @DoniaMarco @YGaritaonaindia et al! 👇👇

📣 Our new paper in @JNCCN: acquired resistance to #immunotherapy (ARI) across 11 tumor types Reconstructed IPD: 15,199 pts / 41 phase 3 trials • 73.5% develop ARI by 3y • Higher CR/PR → less ARI, regardless of tumor type ARI may be determined by response depth, not histology Cheers to @DoniaMarco & @CCITdk 🇩🇰 Full paper 👇👇👇

I always appreciate a critical take, so long as done respectfully. MedTwitter has many cheerleaders. Balance is needed.

A tale of two diseases 1/2

Finally...

I find it increasingly concerning how we sometimes present oncology data , even when the results are genuinely impressive. Do we cure patients here? No. Nearly all patients in this study had progressed within 12 months. Does that diminish the importance of the results? Absolutely not. Reaching a mOS 13.2 here in a disease as challenging as pancreatic cancer is a remarkable achievement and an important step forward. But can we, for once, resist the temptation to overhype every positive study? Patients often do not grasp the nuances that oncologists and researchers understand. Terms such as “breakthrough,” “game changer,” or “historic” can easily be interpreted as meaning that a cure is around the corner, when that is simply not the reality. Our responsibility is not only to celebrate progress, but also to communicate it accurately. Presenting excellent results without exaggeration is harder than generating excitement, but it is a far more important obligation IMHO Scientific rigor should apply not only to how we conduct studies, but also to how we discuss them.

#ASCO26 #TRITON @FSkoulidis I’m struggling to understand the value of highlighting secondary endpoints while the primary endpoint remains blinded. The reported improvements in ORR and DoR for tremelimumab durvalumab chemotherapy versus pembrolizumab chemotherapy are numerical rather than compelling, and small patient numbers. Without the 1ry endpoint, it is impossible to know whether these findings represent a meaningful clinical advance or simply noise. Let’s wait for the study to read out before drawing conclusions. #NSCLC #LCSM

Since management of High Risk-Smoldering Multiple #Myeloma often comes up in clinic these days (and leads to spirited discussions with trainees and colleagues), sharing my approach here on how I counsel patients on the use of single-agent daratumumab. I am genuinely excited though about fixed-duration BCMA BsAbs in selected patients, and looking forward to more data in coming years!

As #ASCO2026 approaches, we will once again celebrate the extraordinary progress oncology has achieved over the past decades:targeted therapies, immunotherapy, ADCs, precision medicine, and innovations that are transforming patients’ lives. Yet, at the same time, I find it deeply troubling that we are facing global shortages of old but essential chemotherapy drugs that still save lives every single day in our clinics. How can it be acceptable that a cheap, old drug such as ifosfamide risks becoming unavailable simply because producing it is no longer sufficiently profitable? This is not a scientific failure. It is a systemic and political failure. If healthcare systems and governments do not actively safeguard the supply of essential generic medicines, shortages like this will only become more frequent. Perhaps, while gathering at major international meetings celebrating innovation, we should also remember that many patients still depend on “old” drugs and that innovation means little if essential treatments disappear. ema.europa.eu/en/medicines/h… #oncology #cancer #chemotherapy #DrugShortage #ASCO @myESMO @OncoAlert

Are "healthy people" an endangered species? Someone who hasn't had enough tests drvinayprasad.com/p/what-is-… via @VPrasadMDMPH

Very nice thread, looking forward to the presentation ! #ASCO26 low-dose immunotherapy in lung - Tata Memorial - @Nandinimenon18 et al! #LBA1510 @Alfdoc2

Everyone should read this before treating smoldering myeloma. Evolving challenges in smoldering myeloma trials: shifting endpoint measurement and definitions - ScienceDirect sciencedirect.com/science/ar…

Additional Insights Into Early Daraxonrasib Data: @Timothee_MD takes a deep dive into the early-phase data on daraxonrasib in patients with metastatic pancreatic cancer, just published in @NEJM theoncologyshot.com/p/additi…

"Additional Insights Into Early Daraxonrasib Data" How response rates compare with prior data, and other insights. Let's get prepared for #ASCO26! Full and free here: theoncologyshot.com/p/additi…

Our new article is out in EJC with Sahar van Waalwijk and David Thomas! Reimbursement decisions may be less strongly backed by clinical evidence and more driven by the unmet needs, e.g. reimbursement in childhood cancers where the data are only available for adults. However, this is unprecedented in any public healthcare:  In Australia, the PBAC is reimbursing ipilimumab plus nivolumab for tumour‑agnostic use, even though the DART trial showed an overall response rate of only 12%, with significant toxicities. Read why we believe such a reimbursement decision is unwarranted, and what alternatives we propose. theoncologyshot.com/p/world-…

🚨EXCLUSIVE: FDA official Tracy Høeg fired after refusing to resign @TracyBethHoeg says she first learned about rumours of her departure through media reports before being told by FDA officials to resign or be terminated. LINK below 👇👇 @MartyMakary @VPrasadMDMPH @SecKennedy @AlecGaffney @LizzyLaw_ @maxonwifi @TheChiefNerd @newstart_2024

Congrats for the amazing work you did at the @US_FDA Tracy, you are an outsanding researcher and leader. I'm sure your will contribute to even greater achievements for patients and the society in the future. @TracyBethHoeg : “Marty and I, and Vinay as well, I think we all leave holding our heads high because we refused to bow to political pressure and to pressure from lobbyists to do things in order to keep our jobs or protect our reputations.”

Great exchange of ideas at #ESMOInFocus Lung Cancer Romania 🇷🇴.Honored to participate in this excellent meeting focused on the evolving landscape of thoracic oncology.Pleased to share the stage with outstanding colleagues @gbanna74 @MARIANOPROVENCI #ESMOInFocus